The majority of SARS-CoV-2-specific antibodies in COVID-19 patients with obesity are autoimmune and not neutralizing.
Journal
International journal of obesity (2005)
ISSN: 1476-5497
Titre abrégé: Int J Obes (Lond)
Pays: England
ID NLM: 101256108
Informations de publication
Date de publication:
02 2022
02 2022
Historique:
received:
19
07
2021
accepted:
25
10
2021
revised:
20
10
2021
pubmed:
9
11
2021
medline:
3
2
2022
entrez:
8
11
2021
Statut:
ppublish
Résumé
Obesity decreases the secretion of SARS-CoV-2-specific IgG antibodies in the blood of COVID-19 patients. How obesity impacts the quality of the antibodies secreted, however, is not understood. Therefore, the objective of this study is to evaluate the presence of neutralizing versus autoimmune antibodies in COVID-19 patients with obesity. Thirty serum samples from individuals who tested positive for SARS-CoV-2 infection by RT-PCR were collected from inpatient and outpatient settings. Of these, 15 were lean (BMI < 25) and 15 were obese (BMI ≥ 30). Control serum samples were from 30 uninfected individuals, age-, gender-, and BMI-matched, recruited before the current pandemic. Neutralizing and autoimmune antibodies were measured by ELISA. IgG autoimmune antibodies were specific for malondialdehyde (MDA), a marker of oxidative stress and lipid peroxidation, and for adipocyte-derived protein antigens (AD), markers of virus-induced cell death in the obese adipose tissue. SARS-CoV-2 infection induces neutralizing antibodies in all lean but only in few obese COVID-19 patients. SARS-CoV-2 infection also induces anti-MDA and anti-AD autoimmune antibodies more in lean than in obese patients as compared to uninfected controls. Serum levels of these autoimmune antibodies, however, are always higher in obese versus lean COVID-19 patients. Moreover, because the autoimmune antibodies found in serum samples of COVID-19 patients have been correlated with serum levels of C-reactive protein (CRP), a general marker of inflammation, we also evaluated the association of anti-MDA and anti-AD antibodies with serum CRP and found a positive association between CRP and autoimmune antibodies. Our results highlight the importance of evaluating the quality of the antibody response in COVID-19 patients with obesity, particularly the presence of autoimmune antibodies, and identify biomarkers of self-tolerance breakdown. This is crucial to protect this vulnerable population at higher risk of responding poorly to infection with SARS-CoV-2 than lean controls.
Sections du résumé
BACKGROUND/OBJECTIVES
Obesity decreases the secretion of SARS-CoV-2-specific IgG antibodies in the blood of COVID-19 patients. How obesity impacts the quality of the antibodies secreted, however, is not understood. Therefore, the objective of this study is to evaluate the presence of neutralizing versus autoimmune antibodies in COVID-19 patients with obesity.
SUBJECTS/METHODS
Thirty serum samples from individuals who tested positive for SARS-CoV-2 infection by RT-PCR were collected from inpatient and outpatient settings. Of these, 15 were lean (BMI < 25) and 15 were obese (BMI ≥ 30). Control serum samples were from 30 uninfected individuals, age-, gender-, and BMI-matched, recruited before the current pandemic. Neutralizing and autoimmune antibodies were measured by ELISA. IgG autoimmune antibodies were specific for malondialdehyde (MDA), a marker of oxidative stress and lipid peroxidation, and for adipocyte-derived protein antigens (AD), markers of virus-induced cell death in the obese adipose tissue.
RESULTS
SARS-CoV-2 infection induces neutralizing antibodies in all lean but only in few obese COVID-19 patients. SARS-CoV-2 infection also induces anti-MDA and anti-AD autoimmune antibodies more in lean than in obese patients as compared to uninfected controls. Serum levels of these autoimmune antibodies, however, are always higher in obese versus lean COVID-19 patients. Moreover, because the autoimmune antibodies found in serum samples of COVID-19 patients have been correlated with serum levels of C-reactive protein (CRP), a general marker of inflammation, we also evaluated the association of anti-MDA and anti-AD antibodies with serum CRP and found a positive association between CRP and autoimmune antibodies.
CONCLUSIONS
Our results highlight the importance of evaluating the quality of the antibody response in COVID-19 patients with obesity, particularly the presence of autoimmune antibodies, and identify biomarkers of self-tolerance breakdown. This is crucial to protect this vulnerable population at higher risk of responding poorly to infection with SARS-CoV-2 than lean controls.
Identifiants
pubmed: 34744161
doi: 10.1038/s41366-021-01016-9
pii: 10.1038/s41366-021-01016-9
pmc: PMC8572364
doi:
Substances chimiques
Antibodies, Neutralizing
0
Antibodies, Viral
0
Autoantibodies
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
427-432Subventions
Organisme : NIA NIH HHS
ID : R01 AG023717
Pays : United States
Organisme : NIA NIH HHS
ID : R01 AG032576
Pays : United States
Organisme : NIA NIH HHS
ID : R56 AG059719
Pays : United States
Commentaires et corrections
Type : UpdateOf
Informations de copyright
© 2021. The Author(s).
Références
Henderson LA, Canna SW, Schulert GS, Volpi S, Lee PY, Kernan KF, et al. On the alert for cytokine storm: immunopathology in COVID-19. Arthritis Rheumatol. 2020;72:1059–63.
doi: 10.1002/art.41285
Franceschi C, Bonafe M, Valensin S, Olivieri F, De Luca M, Ottaviani E, et al. Inflamm-aging. An evolutionary perspective on immunosenescence. Ann NY Acad Sci. 2000;908:244–54.
doi: 10.1111/j.1749-6632.2000.tb06651.x
Mueller AL, McNamara MS, Sinclair DA. Why does COVID-19 disproportionately affect older people? Aging. 2020;12:9959–81.
doi: 10.18632/aging.103344
Frasca D, Diaz A, Romero M, Garcia D, Blomberg BB. B cell immunosenescence. Annu Rev Cell Dev Biol. 2020;36:551–74.
doi: 10.1146/annurev-cellbio-011620-034148
Newton AH, Cardani A, Braciale TJ. The host immune response in respiratory virus infection: balancing virus clearance and immunopathology. Semin Immunopathol. 2016;38:471–82.
doi: 10.1007/s00281-016-0558-0
Casadevall A, Pirofski LA. The convalescent sera option for containing COVID-19. J Clin Invest. 2020;130:1545–8.
doi: 10.1172/JCI138003
Duan K, Liu B, Li C, Zhang H, Yu T, Qu J, et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci USA. 2020;117:9490–6.
doi: 10.1073/pnas.2004168117
Langhi DM, Santis GC, Bordin JO. COVID-19 convalescent plasma transfusion. Hematol Transfus Cell Ther. 2020;42:113–5.
doi: 10.1016/j.htct.2020.04.003
Falagas ME, Kompoti M. Obesity and infection. Lancet Infect Dis. 2006;6:438–46.
doi: 10.1016/S1473-3099(06)70523-0
Karlsson EA, Beck MA. The burden of obesity on infectious disease. Exp Biol Med. 2010;235:1412–24.
doi: 10.1258/ebm.2010.010227
O’Shea D, Corrigan M, Dunne MR, Jackson R, Woods C, Gaoatswe G, et al. Changes in human dendritic cell number and function in severe obesity may contribute to increased susceptibility to viral infection. Int J Obes. 2013;37:1510–3.
doi: 10.1038/ijo.2013.16
Frasca D, Ferracci F, Diaz A, Romero M, Lechner S, Blomberg BB. Obesity decreases B cell responses in young and elderly individuals. Obesity. 2016;24:615–25.
doi: 10.1002/oby.21383
Ovsyannikova IG, White SJ, Larrabee BR, Grill DE, Jacobson RM, Poland GA. Leptin and leptin-related gene polymorphisms, obesity, and influenza A/H1N1 vaccine-induced immune responses in older individuals. Vaccine. 2014;32:881–7.
doi: 10.1016/j.vaccine.2013.12.009
Sheridan PA, Paich HA, Handy J, Karlsson EA, Hudgens MG, Sammon AB, et al. Obesity is associated with impaired immune response to influenza vaccination in humans. Int J Obes. 2012;36:1072–7.
doi: 10.1038/ijo.2011.208
George MD, Baker JF. The obesity epidemic and consequences for rheumatoid arthritis care. Curr Rheumatol Rep. 2016;18:6.
doi: 10.1007/s11926-015-0550-z
Ritter A, Kreis NN, Louwen F. Yuan J. Obesity and COVID-19: molecular mechanisms linking both pandemics. Int J Mol Sci. 2020;21:5793.
doi: 10.3390/ijms21165793
Lighter J, Phillips M, Hochman S, Sterling S, Johnson D, Francois F, et al. Obesity in patients younger than 60 years is a risk factor for COVID-19 hospital admission. Clin Infect Dis. 2020;71:896–7.
doi: 10.1093/cid/ciaa415
Nilles EJ, Siddiqui SM, Fischinger S, Bartsch YC, de Saint Aubin M, Zhou G, et al. Epidemiological and immunological features of obesity and SARS-CoV-2. medRxiv:2020.11.11.20229724 [Preprint]. 2020 [cited 2020 Dec 11]: [22 p.]. Available from: https://doi.org/10.1101/2020.11.11.20229724 .
Frasca D, Reidy L, Cray C, Diaz A, Romero M, Kahl K, et al. Influence of obesity on serum levels of SARS-CoV-2-specific antibodies in COVID-19 patients. PLoS ONE. 2021;16:e0245424.
doi: 10.1371/journal.pone.0245424
Woodruff M, Ramonell R, Lee E-H, Sanz I. Clinically identifiable autoreactivity is common in severe SARS-CoV-2 infection. medRxiv:10.1101/2020.10.21.20216192 [Preprint]. 2020 [cited 2020 Oct 28]: [8 p.]. Available from: https://doi.org/10.1101/2020.10.21.20216192 .
Frasca D, Diaz A, Romero M, Blomberg BB. Phenotypic and functional characterization of double negative B cells in the blood of individuals with obesity. Front Immunol. 2021;12:616650.
doi: 10.3389/fimmu.2021.616650
Frasca D, Diaz A, Romero M, Garcia D, Jayram D, Thaller S, et al. Identification and characterization of adipose tissue-derived human antibodies with “anti-self” specificity. Front Immunol. 2020;11:392.
doi: 10.3389/fimmu.2020.00392
Frasca D, Diaz A, Romero M, Thaller S, Blomberg BB. Secretion of autoimmune antibodies in the human subcutaneous adipose tissue. PLoS ONE. 2018;13:e0197472.
doi: 10.1371/journal.pone.0197472
Frasca D, Diaz A, Romero M, Thaller S, Blomberg BB. Metabolic requirements of human pro-inflammatory B cells in aging and obesity. PLoS ONE. 2019;14:e0219545.
doi: 10.1371/journal.pone.0219545
Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248–54.
doi: 10.1016/0003-2697(76)90527-3
Sankhla M, Sharma TK, Mathur K, Rathor JS, Butolia V, Gadhok AK, et al. Relationship of oxidative stress with obesity and its role in obesity induced metabolic syndrome. Clin Lab. 2012;58:385–92.
pubmed: 22783566
Yesilbursa D, Serdar Z, Serdar A, Sarac M, Coskun S, Jale C. Lipid peroxides in obese patients and effects of weight loss with orlistat on lipid peroxides levels. Int J Obes. 2005;29:142–5.
doi: 10.1038/sj.ijo.0802794
Caso F, Costa L, Ruscitti P, Navarini L, Del Puente A, Giacomelli R, et al. Could SARS-coronavirus-2 trigger autoimmune and/or autoinflammatory mechanisms in genetically predisposed subjects? Autoimmun Rev. 2020;19:102524.
doi: 10.1016/j.autrev.2020.102524
Gagiannis D, Steinestel J, Hackenbroch C, Schreiner B, Hannemann M, Bloch W, et al. Clinical, serological, and histopathological similarities between severe COVID-19 and acute exacerbation of connective tissue disease-associated interstitial lung disease (CTD-ILD). Front Immunol. 2020;11:587517.
doi: 10.3389/fimmu.2020.587517
Lin YS, Lin CF, Fang YT, Kuo YM, Liao PC, Yeh TM, et al. Antibody to severe acute respiratory syndrome (SARS)-associated coronavirus spike protein domain 2 cross-reacts with lung epithelial cells and causes cytotoxicity. Clin Exp Immunol. 2005;141:500–8.
doi: 10.1111/j.1365-2249.2005.02864.x
Gunnarsson A, Hellmark T, Wieslander J. Molecular properties of the Goodpasture epitope. J Biol Chem. 2000;275:30844–8.
doi: 10.1074/jbc.M004717200
Reynolds J, Moss J, Duda MA, Smith J, Karkar AM, Macherla V, et al. The evolution of crescentic nephritis and alveolar haemorrhage following induction of autoimmunity to glomerular basement membrane in an experimental model of Goodpasture’s disease. J Pathol. 2003;200:118–29.
doi: 10.1002/path.1336
Wan SW, Lin CF, Yeh TM, Liu CC, Liu HS, Wang S, et al. Autoimmunity in dengue pathogenesis. J Formos Med Assoc. 2013;112:3–11.
doi: 10.1016/j.jfma.2012.11.006
Luo X, Zhou W, Yan X, Guo T, Wang B, Xia H, et al. Prognostic value of C-reactive protein in patients with COVID-19. Clin Infect Dis. 2020;71:2174–9.
doi: 10.1093/cid/ciaa641
Manson JJ, Crooks C, Naja M, Ledlie A, Goulden B, Liddle T, et al. COVID-19-associated hyperinflammation and escalation of patient care: a retrospective longitudinal cohort study. Lancet Rheumatol. 2020;2:e594–602.
doi: 10.1016/S2665-9913(20)30275-7
Velavan TP, Meyer CG. Mild versus severe COVID-19: laboratory markers. Int J Infect Dis. 2020;95:304–7.
doi: 10.1016/j.ijid.2020.04.061
Wang L. C-reactive protein levels in the early stage of COVID-19. Med Mal Infect. 2020;50:332–4.
doi: 10.1016/j.medmal.2020.03.007
Woodruff MC, Ramonell RP, Saini AS, Haddad NS, Anam FA, Rudolph ME, et al. Relaxed peripheral tolerance drives broad de novo autoreactivity in severe COVID-19. medRxiv:10.1101/2020.10.21.20216192 [Preprint]. 2021 [cited 2021 Jul 21]: [29 p.]. Available from: https://doi.org/10.1101/2020.10.21.20216192 .
Woodruff MC, Ramonell RP, Nguyen DC, Cashman KS, Saini AS, Haddad NS, et al. Extrafollicular B cell responses correlate with neutralizing antibodies and morbidity in COVID-19. Nat Immunol. 2020;21:1506–16.
doi: 10.1038/s41590-020-00814-z
Hotamisligil GS. Inflammation, metaflammation and immunometabolic disorders. Nature. 2017;542:177–85.
doi: 10.1038/nature21363
Mayer-Pickel K. Obesity and antiphospholipid syndrome: a particular challenge in pregnancy. Obes Res. 2015;2:46–56.